Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Interest & Investment Income (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Interest & Investment Income data on record, last reported at $4.8 million in Q1 2026.

  • On a quarterly basis, Interest & Investment Income rose 5.57% to $4.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $16.5 million, a 18.93% increase, with the full-year FY2025 number at $16.2 million, up 27.93% from a year prior.
  • Interest & Investment Income reached $4.8 million in Q1 2026 per OLMA's latest filing, up from $4.0 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for OLMA hit a ceiling of $4.8 million in Q1 2026 and a floor of $218000.0 in Q1 2022.
  • A 5-year average of $2.6 million and a median of $3.1 million in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 792.66% in 2022, then decreased 7.24% in 2024.
  • Tracing OLMA's Interest & Investment Income over 5 years: stood at $973000.0 in 2022, then surged by 264.95% to $3.6 million in 2023, then decreased by 7.24% to $3.3 million in 2024, then rose by 21.74% to $4.0 million in 2025, then grew by 19.1% to $4.8 million in 2026.
  • Business Quant data shows Interest & Investment Income for OLMA at $4.8 million in Q1 2026, $4.0 million in Q4 2025, and $3.6 million in Q3 2025.